Will Califf’s Attention To Foods Come At Expense Of US FDA’s Drugs Program?
Executive Summary
FDA Commissioner Robert Califf says the medical product programs have received a lot of attention and now it’s the food program’s turn.
You may also be interested in...
Pharma Remains In US FDA Back Seat As Food, Tobacco Priorities Take Center Stage
FDA Deputy Commissioner for Policy, Legislation and International Affairs Kimberlee Trzeciak has non-medical product work at top of her agenda, highlighting shift in attention that has been a mainstay of FDA commissioner Robert Califf's tenure.
Pharma Continues To Sit In Back Seat As Tobacco, Food Priorities Take Center Stage At FDA
New FDA Deputy Commissioner for Policy, Legislation and International Affairs Kimberlee Trzeciak has non-medical product work on the top of her agenda, highlighting the shift in attention that has been a mainstay of FDA commissioner Robert Califf's tenure.
Batch Testing Of All Imported Drugs Floated At House Appropriations Hearing
While food oversight dominated lawmakers' attention, Republicans and Democrats were united on need to onshore more drug manufacturing to the US as FDA Commissioner Robert Califf testified about the agency’s fiscal year 2024 budget request.